Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 64

1.

Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist.

Raza S, Safyan RA, Rosenbaum E, Bowman AS, Lentzsch S.

Ther Adv Hematol. 2017 Feb;8(2):55-70. doi: 10.1177/2040620716680548. Review.

2.

The role of the proteasome in AML.

Csizmar CM, Kim DH, Sachs Z.

Blood Cancer J. 2016 Dec 2;6(12):e503. doi: 10.1038/bcj.2016.112. Review.

3.

A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma.

Franken B, van de Donk NW, Cloos JC, Zweegman S, Lokhorst HM.

Ther Adv Hematol. 2016 Dec;7(6):330-344. Review.

4.

Recent advances in multiple myeloma: a Korean perspective.

Hong J, Lee JH.

Korean J Intern Med. 2016 Sep;31(5):820-34. doi: 10.3904/kjim.2015.408. Review.

5.

Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice.

Lee HS, Min CK.

Korean J Intern Med. 2016 Sep;31(5):809-19. doi: 10.3904/kjim.2016.110. Review.

6.

Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma : a meta-analysis of 37 trials.

Zou Y, Ma X, Yu H, Hu C, Fan L, Ran X.

Oncotarget. 2016 Jul 21. doi: 10.18632/oncotarget.10768. [Epub ahead of print] Review.

7.

Computational Approaches for the Discovery of Human Proteasome Inhibitors: An Overview.

Guedes RA, Serra P, Salvador JA, Guedes RC.

Molecules. 2016 Jul 16;21(7). pii: E927. doi: 10.3390/molecules21070927. Review.

8.

Novel agents in the treatment of multiple myeloma: a review about the future.

Naymagon L, Abdul-Hay M.

J Hematol Oncol. 2016 Jun 30;9(1):52. doi: 10.1186/s13045-016-0282-1. Review.

9.

Treatment of relapsed and refractory multiple myeloma.

Sonneveld P, Broijl A.

Haematologica. 2016 Apr;101(4):396-406. doi: 10.3324/haematol.2015.129189. Review.

10.

Molecular mechanisms for synergistic effect of proteasome inhibitors with platinum-based therapy in solid tumors.

Chao A, Wang TH.

Taiwan J Obstet Gynecol. 2016 Feb;55(1):3-8. doi: 10.1016/j.tjog.2015.12.004. Review.

11.

Spotlight on ixazomib: potential in the treatment of multiple myeloma.

Muz B, Ghazarian RN, Ou M, Luderer MJ, Kusdono HD, Azab AK.

Drug Des Devel Ther. 2016 Jan 11;10:217-26. doi: 10.2147/DDDT.S93602. Review.

12.

Multiple Myeloma: Diagnosis and Treatment.

Rajkumar SV, Kumar S.

Mayo Clin Proc. 2016 Jan;91(1):101-19. doi: 10.1016/j.mayocp.2015.11.007. Review.

13.

Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat.

Afifi S, Michael A, Azimi M, Rodriguez M, Lendvai N, Landgren O.

Pharmacotherapy. 2015 Dec;35(12):1173-88. doi: 10.1002/phar.1671. Review.

14.

Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics.

Dimopoulos MA, Kastritis E, Ghobrial IM.

Ann Oncol. 2016 Feb;27(2):233-40. doi: 10.1093/annonc/mdv572. Review.

15.

Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling.

Accardi F, Toscani D, Bolzoni M, Dalla Palma B, Aversa F, Giuliani N.

Biomed Res Int. 2015;2015:172458. doi: 10.1155/2015/172458. Review.

16.

Myeloma today: Disease definitions and treatment advances.

Rajkumar SV.

Am J Hematol. 2016 Jan;91(1):90-100. doi: 10.1002/ajh.24236. Review. Erratum in: Am J Hematol. 2016 Sep;91(9):965.

17.

Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.

Shay G, Hazlehurst L, Lynch CC.

J Mol Med (Berl). 2016 Jan;94(1):21-35. doi: 10.1007/s00109-015-1345-4. Review.

18.

Thrombotic microangiopathy associated with proteasome inhibitors.

Lodhi A, Kumar A, Saqlain MU, Suneja M.

Clin Kidney J. 2015 Oct;8(5):632-6. doi: 10.1093/ckj/sfv059. Review.

19.

Deubiquitinases (DUBs) and DUB inhibitors: a patent review.

Farshi P, Deshmukh RR, Nwankwo JO, Arkwright RT, Cvek B, Liu J, Dou QP.

Expert Opin Ther Pat. 2015;25(10):1191-208. doi: 10.1517/13543776.2015.1056737. Review.

20.

Multiple myeloma: from front-line to relapsed therapies.

Moreau P, Touzeau C.

Am Soc Clin Oncol Educ Book. 2015:e504-11. doi: 10.14694/EdBook_AM.2015.35.e504. Review.

Items per page

Supplemental Content

Loading ...
Support Center